Mallinckrodt — Merger or Acquisition (August 2025)
87 slides from Mallinckrodt's merger presentation, Aug 1, 2025
Slide 1: Par Health Deal - basis financial information presentation
Par Health Deal - basis financial information presentation
Slide 2: Table of contents
Table of contents 2 July 2025 | Par Health Page 2 Summary of findings Business overview Quality of earnings Recast income statement Working capital Appendix 1 2 3 4 5 6 3 10 16 48 69 78
Slide 3: Summary of findings
Summary of findings © Mallinckrodt Pharmaceuticals
Slide 4: Standalone and synergies, diligence adjusted net sales and EBITDA
Standalone and synergies Diligence adjusted gross profit Diligence adjusted net sales Diligence EBITDA $(35.0)m $728.5m $1,672.0m $509.8m TTMMar25 net standalone costs and synergies In TTMMar25 In TTMMar25 In TTMMar25 Management’s estimate of standalone costs and identified synergies are $ 57 . 7 m
Slide 5: Key considerations
Key considerations SAC and synergy Endo GxSI Combined MNK SGx Summary of findings Business overview Quality of earnings Recast income statement Working capital Appendix In March 2025 MNK and Endo announced a merger to form a Combined company, with the transaction planned to close in the second half
Slide 6: TTMMar25 adjusted net sales by type
Other MNK SGx 13.9 $1,672.0m TTMMar25 adjusted net sales Adjusted net sales decreased $147.4m (8.1%) from $1,819.4m in FY23 to $1,672.0m in TTMMar25. TTMMar25 adjusted net sales by type The overall decrease in net sales from FY23 to TTMMar25 was mainly driven by: ▪ $ 203 . 3 m ( 28 . 0 % ) decrease
Slide 7: Key considerations: gross margin
Key considerations Gross margin : Decreased 4 . 0 ppts from 47 . 6 % in FY 23 to 43 . 6 % in TTMMar 25 primarily driven by : ▪ A 12 . 3 % decrease in Endo GxSI gross margin resulting from (i) pricing pressure due to increased generics market competition, (ii) increased production costs at CMOs for c
Slide 8: EBITDA bridge FY23 to TTMMar25
659.2 568.2 509.8 22.2 0.6 (113.9) (33.5) (12.2) (12.7) 400.0 450.0 500.0 550.0 600.0 650.0 700.0 EBITDA FY23 Net sales Cost of sales Operating expenses EBITDA FY24 Net sales Cost of sales Operating expenses EBITDA TTMMar25 Currency: $ m Key considerations FY23 to FY24 • 1 Sales : The decrease in ne
Slide 9: Key considerations: net working capital
Key considerations SAC and synergy Endo GxSI Combined MNK SGx Summary of findings Business overview Quality of earnings Recast income statement Working capital Appendix ▪ Diligence adjusted NWC is presented net of (i) definitional adjustments, including cash and cash equivalents and debt items and (
Slide 10: Business overview
Business overview © Mallinckrodt Pharmaceuticals
Slide 11: Extensive diversified generic and sterile injectable product portfolio
The Combined Business has an extensive diversified generic and sterile injectable product portfolio and will be called Par Health. The Combined Business manufactures and sells the following products (as illustrated in the chart at left): containing tablets, oxycodone - containing tablets and other c
Slide 12: Headquarters, manufacturing and FTEs
The Combined Business has headquarters in Webster Groves, MO, and Malvern, PA, with production facilities located in the US and India. Manufacturing and FTEs The Combined Business is headquartered in Webster Groves, MO and Malvern, PA with a combined 3 , 657 FTEs ( 1 , 604 at MNK SGx and 2 , 053 at
Slide 13: Basis of presentation of combined financial information
Combined financial information in this report represents MNK SGx and Endo GxSI in addition to a combined standalone cost and synergy analysis. The below represents a summary of the basis of presentation for the combined Business. See subsequent page for detailed descriptions. SAC and synergies Endo
Slide 14: Basis of presentation of financial information – MNK SGx
MNK SGX financial information presented in this report represents dedicated MNK SGx entities, excluding shared service allocations. Basis of presentation of financial information – MNK SGx Balance sheet : Historical financial information of MNK SGx, a reportable segment of MNK, was The deal basis ba
Slide 15: Basis of presentation – Endo GxSI
Endo GxSI financial information presented in this report represents direct revenue and costs identified in dedicated profit and cost centers for Endo GxSI. Basis of presentation Deal Basis vs. Carve - out financial information Management represented Endo’s reporting segments are identified by profit
Slide 16: Quality of earnings
Quality of earnings Quality of earnings - MNK SGx Quality of earnings – Endo GxSI
Slide 17: Combined standalone EBITDA quality of earnings
Combined Standalone EBITDA is $474.8m as of TTMMar25, and includes $(57.7)m of SAC and $22.7m of synergies identified by Management. The table below represents the combining quality of earnings for Par Health . As previously noted, this does not constitute a GAAP consolidation of Par Health . See fo
Slide 18: Quality of earnings - MNK SGx
Quality of earnings - MNK SGx © Mallinckrodt Pharmaceuticals
Slide 19: MNK SGx quality of earnings overview
Diligence EBITDA increased from $217.1m in FY23 to $298.8m in TTMMar25. Proposed adjustments increased reported EBITDA by $99.1m in TTMMar25. Quality of earnings overview The table at left presents the reconciliation from Reported EBITDA to Diligence EBITDA for the Historical Period . Refer to the d
Slide 20: Management adjustments: bankruptcy items
42.4 39.5 45.1 2 Intercompany 0.8 1.1 (0.6) 3 Other - - 85.8 4 Impairment 99.1 126.2 (379.0) Management adjustments 298.8 299.1 205.4 Management EBITDA (0.0) 5.3 11.7 Diligence adjustments 298.8 304.3 217.1 Diligence EBITDA Bankruptcy items : Management removes from EBITDA the income, expenses, gain
Slide 21: Management adjustments: intercompany
Currency: $ m Ref. FY23 FY24 TTMMar25 Reported EBITDA 584.4 172.9 199.7 Bankruptcy items 1 (509.3) 85.5 55.9 Intercompany 2 45.1 39.5 42.4 Other 3 (0.6) 1.1 0.8 Impairment 4 85.8 - - Management adjustments (379.0) 126.2 99.1 Management EBITDA 205.4 299.1 298.8 Diligence adjustments 11.7 5.3 (0.0) Di
Slide 22: Management adjustments: other and impairment
Other items excluded from Management EBITDA in TTMMar25 include foreign currency gains and losses. Management adjustments: Other : Costs added back primarily represent foreign currency gains and losses . Management removes foreign currency impact, both realized and unrealized from EBITDA . MNK SGx i
Slide 23: Pro forma adjustments: Fentanyl Patch disruption
Pro forma adjustments for Fentanyl Patch disruption further increase EBITDA by $5.8m in TTM25. Diligence adjustments: Pro forma : Adjustments for business disruptions and discontinuations on a pro forma basis are as follows : i. Fentanyl Patch disruption : In the beginning of FY 23 MNK SGx was force
Slide 24: Pro forma adjustments: Fentanyl Patch (continued)
TTMMar25 FY24 FY23 Ref. Currency: $ m 199.7 172.9 584.4 A Reported EBITDA 298.8 299.1 205.4 B Management EBITDA 5.8 4.4 10.2 5 Pro forma Pro forma adjustments for Fentanyl Patch disruption further increase EBITDA by $5.8m in TTM25. Diligence adjustments: Pro forma (continued): i. Fentanyl Patch disr
Slide 25: One-time / non-recurring adjustments
TTMMar25 FY24 FY23 Ref. Currency: $ m 199.7 172.9 584.4 A Reported EBITDA 298.8 299.1 205.4 B Management EBITDA Diligence adjustments for one - time/non - recurring items increase EBITDA by $3.5m in TTMMar25. Diligence adjustments: One - time / non - recurring: Adjustments for one - time / non - rec
Slide 26: One-time / non-recurring adjustments (continued)
TTMMar25 FY24 FY23 Ref. Currency: $ m 1.9 2.0 0.4 i CIP project write - off 1.0 1.0 - ii Beetle reserve reversal 0.5 - - iii Asbestos remediation 0.1 0.9 1.1 iv Salary severance and retention 0.0 0.1 0.5 v Big Mac refurbishment - - 1.3 vi Bonus - KEIP removal - - 0.7 vii Vopak adjustments 3.5 4.1 4.
Slide 27: Out-of-period / accounting adjustments
TTMMar25 FY24 FY23 Ref. Currency: $ m (2.3) 0.6 3.1 Bad debt expense, as reported 0.1 0.1 0.1 Average write - offs (2.4) 0.5 3.0 i Bad debt expense adjustment TTMMar25 FY24 FY23 Ref. Currency: $ m 199.7 172.9 584.4 A Reported EBITDA 298.8 299.1 205.4 B Management EBITDA Diligence adjustments for out
Slide 28: Out-of-period / accounting (continued)
TTMMar25 FY24 FY23 Ref. Currency: $ m 199.7 172.9 584.4 A Reported EBITDA 298.8 299.1 205.4 B Management EBITDA Diligence adjustments for out - of - period / accounting items decrease EBITDA by $3.5m in TTMMar25. Diligence adjustments: Out - of - period / accounting (continued) iii. Inventory varian
Slide 29: Out-of-period / accounting adjustments
5.8 4.4 10.2 5 Pro forma 3.5 4.1 4.0 6 One - time / non - recurring (3.5) (0.1) 7.3 7 Out - of - period / accounting (2.4) 4.3 (3.4) 8 Carve - out (3.5) (7.3) (6.4) 9 Non - core / non - operational (0.0) 5.3 11.7 Diligence adjustments 298.8 304.3 217.1 Diligence EBITDA TTMMar25 FY24 FY23 Ref. Curren
Slide 30: Out-of-period / accounting adjustments
5.8 4.4 10.2 5 Pro forma 3.5 4.1 4.0 6 One - time / non - recurring (3.5) (0.1) 7.3 7 Out - of - period / accounting (2.4) 4.3 (3.4) 8 Carve - out (3.5) (7.3) (6.4) 9 Non - core / non - operational (0.0) 5.3 11.7 Diligence adjustments 298.8 304.3 217.1 Diligence EBITDA TTMMar25 FY24 FY23 Ref. Curren
Slide 31: Carve-out adjustments
TTMMar25 FY24 FY23 Ref. Currency: $ m 199.7 172.9 584.4 A Reported EBITDA 298.8 299.1 205.4 B Management EBITDA Diligence adjustments of $(2.4)m in TTMMar25 align the deal basis income statement to the carve - out financial statements. Diligence adjustments: Carve - out: Adjustments to align the dea
Slide 32: Non-core / non-operational adjustments
TTMMar25 FY24 FY23 Ref. Currency: $ m (2.9) (4.9) (0.1) i Gain on disposal of fixed assets (1.3) (2.9) (7.0) ii Pension & employee benefit programs 0.4 0.2 0.4 iii Legal - environmental 0.2 0.3 0.3 iv Idle plant depreciation - Hobart (3.5) (7.3) (6.4) 9 Non - core / non - operational TTMMar25 FY24 F
Slide 33: Quality of earnings – Endo GxSI
Quality of earnings – Endo GxSI
Slide 34: Endo GxSI quality of earnings overview
Currency: $ m Ref FY23 FY24 TTMMar25 (102.9) (61.0) 276.1 Net income (loss) 104.7 111.4 139.1 Depreciation and amortization (0.7) (0.8) (0.8) Interest income, net 104.0 110.6 138.3 Definitional adjustments 1.1 49.6 414.4 A Reported EBITDA 239.9 239.7 (7.8) i Non - cash adjustments (47.0) (48.5) - ii
Slide 35: Management adjustments: non-cash and bankruptcy items
Currency: $ m Ref FY23 FY24 TTMMar25 Net income (loss) 276.1 (61.0) (102.9) Non - cash adjustments ($239.9m in TTMMar25) and bankruptcy related items ($(47.0)m in TTMMar25) are excluded from Management EBITDA. Management adjustments: Non - cash adjustments : Primarily represents (i) impairment of in
Slide 36: Management adjustments: other
1.1 49.6 414.4 Reported EBITDA 239.9 239.7 (7.8) 1 Non - cash adjustments (47.0) (48.5) - 2 Bankruptcy items 2.0 4.7 25.9 3 Other 194.9 195.9 18.1 Management adjustments 196.0 245.5 432.5 Management EBITDA 14.9 18.3 9.6 Diligence adjustments 210.9 263.8 442.1 Diligence EBITDA Currency: $ m Ref FY23
Slide 37: Pro forma adjustment: Indore facility ramp up
TTMMar25 FY24 FY23 Ref Currency: $ m 5.0 4.7 3.3 Personnel 7.8 7.4 4.0 Non - personnel 12.8 12.1 7.3 Cost of sales labor & OH 2.2 1.8 1.3 G&A 1.9 1.9 1.7 R&D 16.9 15.7 10.2 4 Indore facility ramp up cost Currency: $ m Ref FY23 Net income (loss) 276.1 Reported EBITDA 414.4 Management adjustments 18.1
Slide 38: Out-of-period / accounting adjustments
Currency: $ m Ref FY23 Net income (loss) 276.1 Reported EBITDA 414.4 Management adjustments 18.1 Management EBITDA 432.5 Pro forma 4 10.2 Dexlan Deerfield Partnership true - up i 2.1 Partnership true up Q423 ii 2.5 Royalty true up - Vasostrict AG iii 1.6 Other iv 1.0 Out of period / accounting 5 7.3
Slide 39: Out-of-period / accounting adjustments (continued)
Diligence adjustments for out - of - period / accounting adjustments decrease EBITDA by $(3.4)m in TTMMar25. Out - of - period/accounting adjustments (continued) : iii. Royalty true - up for Vasostrict : In Q 223 , Management recorded a true - up of royalty due from Aurobindo . In FY 22 , Endo accru
Slide 40: One-time / non-recurring adjustments
1.2 1.2 - Return for recall of discontinued products 4.7 4.9 (0.2) 6.i GTN charges on discontinued products Diligence adjustments: TTMMar25 FY24 FY23 Ref Currency: $ m (102.9) (61.0) 276.1 Net income (loss) 1.1 49.6 414.4 Reported EBITDA 194.9 195.9 18.1 Management adjustments 196.0 245.5 432.5 Mana
Slide 41: One-time / non-recurring (continued)
Currency: $ m Ref FY23 Net income (loss) 276.1 Reported EBITDA 414.4 Management adjustments 18.1 Management EBITDA 432.5 FY24 TTMMar25 (61.0) (102.9) 49.6 1.1 195.9 194.9 245.5 196.0 15.7 16.9 0.9 (3.4) Pro forma 4 10.2 Out of period / accounting 5 7.3 Diligence adjustments for one - time/non - recu
Slide 42: One-time / non-recurring adjustments
Currency: $ m Ref FY23 Net income (loss) 276.1 Reported EBITDA 414.4 Management adjustments 18.1 Management EBITDA 432.5 Pro forma 4 10.2 Out of period / accounting 5 7.3 GTN charges on disc. products i (0.2) Vendor credit ii 4.0 Varenicline royalty settlement iii 2.8 Excess inventory reserve iv 9.1
Slide 43: Excess inventory reserve (continued)
Currency: $ m Ref FY23 FY24 TTMMar25 Diligence adjustments for one - time/non - recurring items increase EBITDA by $1.3m in TTMMar25. Diligence adjustments: e - time / non - recurring (continued): Excess inventory reserve (continued) e. - - 1.3 a Everolimus - (0.0) 2.3 a Argatroban (0.2) 0.3 1.0 b P
Slide 44: Problem lot inventory write-off
4.7 4.9 (0.2) i GTN charges on disc. products (3.2) (3.2) 4.0 ii Vendor credit (0.7) 0.1 2.8 iii Varenicline royalty settlement 0.2 0.3 9.1 iv Excess inventory reserve 0.2 2.0 7.2 v Problem lot inv. write off - (2.3) 2.3 vi Short - date inventory reserve 0.1 0.2 (28.8) vii Novavax settlement - - (4.
Slide 45: Novavax settlement
Currency: $ m Ref FY23 Net income (loss) 276.1 Reported EBITDA 414.4 Management adjustments 18.1 Management EBITDA 432.5 Pro forma 4 10.2 Out of period / accounting 5 7.3 GTN charges on disc. products i (0.2) Vendor credit ii 4.0 Varenicline royalty settlement iii 2.8 Excess inventory reserve iv 9.1
Slide 46: Carve-out adjustments: allocations from RemainCo
Currency: $ m Ref FY23 Net income (loss) 276.1 Reported EBITDA 414.4 Management adjustments 18.1 Management EBITDA 432.5 Pro forma 4 10.2 Out of period / accounting 5 7.3 One - time / non - recurring 6 (8.0) Carve - out 7 0.1 Diligence adjustments 9.6 Diligence EBITDA 442.1 FY24 TTMMar25 (61.0) (102
Slide 47: Carve-out adjustments: allocations to RemainCo
Currency: $ m Ref FY23 Net income (loss) 276.1 Reported EBITDA 414.4 Management adjustments 18.1 Management EBITDA 432.5 Pro forma 4 10.2 Out of period / accounting 5 7.3 One - time / non - recurring 6 (8.0) Carve - out 7 0.1 Diligence adjustments 9.6 Diligence EBITDA 442.1 FY24 TTMMar25 (61.0) (102
Slide 48: Recast income statement
Recast income statement Recast income statement - MNK SGx Recast income statement - Endo GxSI
Slide 49: Par Health combining recast income statement
TTMMar25 recast income statement reflects Management and diligence EBITDA adjustments and standalone costs. The table below presents the combining recast income statement of Par Health. As previously noted, this does not constitute a GAAP consolidation of Par Health. Refer to the following slides fo
Slide 50: Recast income statement – MNK SGx
Recast income statement – MNK SGx
Slide 51: MNK SGx net sales by product category
258.4 353.5 356.4 108.6 164.7 182.2 222.9 178.5 160.1 106.4 119.0 116.1 74.6 89.7 88.6 - 200.0 400.0 600.0 800.0 1,000.0 FY23 FY24 TTMMar25 Currency: $ (millions) Net sales by product category Opioids ADHD APAP API Others The diligence adjusted income statement reflects both Management and diligence
Slide 52: MNK SGx EBITDA drivers
Increases in EBITDA throughout the Historical Period were primarily driven by an increase of $132.5m in net sales from $770.9m in FY23 to $903.4m in TTMMar25. 1 2 3 4 5 6 7 8 FY23 to FY24 • 1 Sales : The increase in net sales of $134.6m (17.5%) is due to favorable pricing and the new product launch
Slide 53: Gross to net reductions for Generics
Gross to net reductions decreased as a percentage of Generics gross sales throughout the Historical Period from 75.8% in FY23 to 69.8% in TTMMar25. SAC and synergy Endo GxSI Combined MNK SGx Summary of findings Business overview Quality of earnings Recast income statement Working capital Appendix TT
Slide 54: Gross to net reductions discussion
Gross to net reductions decreased as a percentage of Generics gross sales throughout the Historical Period from 75.8% in FY23 to 69.8% in TTMMar25. iii. vii. GPO, distributor & managed care fees ; Represents fees paid for distribution, logistics, administration and inventory management services by M
Slide 55: MNK SGx net sales bridge
770.9 905.4 903.4 95.1 56.1 12.6 15.2 2.9 17.5 700 750 800 850 900 950 Net sales FY23 Opioids ADHD APAP API Others Net sales FY24 Opioids ADHD APAP API Others Net sales TTMMar25 Currency: $ m P: $96.6m V/M: ($1.5m) P: $7.1m V/M: $49.0m P: $2.8m V/M: $9.8m P: $13.6m V/M: $1.6m P: $5.6m V/M: $11.9m (2
Slide 56: MNK SGx net sales by product
MNK SGx net sales by product Currency: $ m FY24 TTMMar25 Hydrocodone - APAP 142.9 142.4 Oxycodone - APAP 70.1 76.0 Oxycodone IR 48.7 48.0 Codeine - APAP 32.1 29.6 Other 60.8 59.7 Opioids 354.6 355.7 Gx Vyvanse 57.4 61.3 Gx Adderall XR 29.6 34.8 Metadate 14.6 15.9 Mixed Salts 12.6 15.6 Other 51.4 54.
Slide 57: Opex personnel costs
As a % of salaries TTMMar25 FY24 FY23 TTMMar25 FY24 FY23 Currency: $ m 100.0 100.0 100.0 22.3 22.0 20.6 Salaries and wages 25.5 28.2 25.3 5.7 6.2 5.2 Bonus 20.4 21.2 23.9 4.6 4.7 4.9 Benefits 9.7 9.2 11.8 2.2 2.0 2.4 Commission 9.1 9.3 8.8 2.0 2.0 1.8 Payroll tax 36.7 37.0 35.0 Opex personnel costs
Slide 58: Non-personnel costs within SG&A
Non - personnel costs within SG&A increased $20.0m (24.0%) in the TTMMar25 period due to increased legal costs. SG&A as a percentage of operating expense increased from 76 . 4 % to 80 . 6 % over the Historical Period due to higher legal spend . An overview of accounts and significant fluctuations ar
Slide 59: Recast income statement – Endo GxSI
Recast income statement – Endo GxSI
Slide 60: Endo GxSI summary income statement and diligence EBITDA
650.5 437.8 433.3 398.0 362.3 335.3 - 1,200.0 1,000.0 800.0 600.0 400.0 200.0 FY23 FY24 TTMMar25 Currency: $ (millions) Endo Gx Endo SI Diligence EBITDA decreased throughout the Historical Period due to increased competition for generic products. The adjacent table presents the summary income statem
Slide 61: Endo GxSI EBITDA bridge
442.1 263.8 210.9 11.9 2.3 (248.4) 139.7 (80.9) (0.5) (31.5) 19.1 (36.3) (6.5) - 150.0 100.0 50.0 300.0 250.0 200.0 500.0 450.0 400.0 350.0 FY23 EBITDA Net sales COGS - margin COGS - volume SG&A R&D FY24 EBITDA Net sales COGS - margin COGS - volume SG&A R&D TTMMar25 EBITDA Currency: $ m Diligence Ad
Slide 62: Endo GxSI gross to net reductions
TTMMar25 FY24 FY23 Currency: $ m 2,488.4 2,526.4 3,186.6 Gross sales Reductions to gross sales: (1,462.5) (1,460.9) (1,740.3) Chargebacks (86.9) (92.5) (143.5) Rebates (49.2) (49.8) (63.0) Cash Discounts (38.6) (39.0) (34.8) Returns (48.4) (49.1) (68.4) GPO (20.7) (15.0) (33.2) Medicaid (22.3) (30.1
Slide 63: Gross to net reductions discussion
Gross to net reductions increased as a percentage of gross sales throughout the Historical Period from 67.9% in FY23 to 70.0% in TTMMar25. iii. vii. ii . Rebates : Primarily represents direct and indirect rebates and inventory admin fees . Rebates are accrued at the point of sale based on the histor
Slide 64: Endo GxSI net sales by top products
Net sales decreased by $279.9m from FY23 to TTMMar25 due to loss of favorable market position for multiple products (Varenicline, Vasostrict, etc.). FY24 TTMMar25 FY23 Currency: $ m The chart above bridges Endo GxSI's net revenue from FY23 to TTMMar25, detailing top products by segment 140.3 145.1 7
Slide 65: Endo SI top 10 products
Net sales decreased by $279.9m from FY23 to TTMMar25 due to loss of favorable market position for multiple products (Varenicline, Vasostrict, etc.). TTMMar25 FY24 FY23 Currency: $ m 145.1 66.2 21.2 18.1 27.1 43.0 320.5 112.8 140.3 74.1 21.5 15.3 29.7 46.8 327.8 110.0 78.5 114.4 25.2 164.9 39.4 48.9
Slide 66: Cost of revenues
Currency: $ m Ref FY23 FY24 TTMMar25 Personnel costs 1 94.8 100.4 102.4 Standard COGS & variances 2 177.8 152.2 175.7 Variable manufacturing OH 3 45.7 53.8 57.2 Royalty expense 4 106.1 62.8 55.3 Inventory provisions 5 47.5 41.9 38.8 Other 6 36.7 38.7 37.6 Non - personnel costs 413.8 349.5 364.6 Cost
Slide 67: R&D and operating expenses
Currency: $ m Ref FY23 Salaries and wages 9.2 Bonus 1.6 Long term incentives 0.8 Other personnel 1.6 Personnel - R&D 13.3 Average R&D FTEs 357 Cost per head ( 000 s) 25 . 9 27 . 3 27 . 8 The table above presents operating expenses segregated by personnel and non - personnel on a diligence adjusted b
Slide 68: SG&A and operating expenses
TTMMar25 FY24 FY23 Ref Currency: $ m 15.2 15.1 14.6 Salaries and wages 3.6 3.4 4.5 Bonus 1.1 2.4 3.0 Long term incentives 3.6 4.0 4.4 Other personnel 23.5 24.9 26.5 i Personnel - SG&A 176.4 175.7 177.8 Average SG&A FTEs 86.3 86.1 82.3 Cost per head (000s) Currency: $ m Ref FY23 Personnel i 26.5 FY24
Slide 69: Working capital
Working capital Working capital - MNK SGx Working capital - Endo GxSI
Slide 70: Par Health combining working capital
A + B = C B A Par Health Endo GxSI MNK SGx TTM Mar25 avg. Mar25 Dec24 Sep24 Jun24 TTM Mar25 avg. Mar25 Dec24 Sep24 Jun24 TTM Mar25 avg. Mar25 Dec24 Sep24 Jun24 Currency: $ m 67.4 73.7 63.6 59.4 73.1 0.2 0.2 0.2 0.2 0.2 67.2 73.5 63.4 59.2 72.9 Cash and cash equivalents 209.5 214.7 241.7 221.6 160.2
Slide 71: Working capital — MNK SGx
Working capital — MNK SGx © Mallinckrodt Pharmaceuticals
Slide 72: MNK SGx diligence adjusted net working capital
Diligence adjusted net working capital increased throughout the Historical Period primarily due to an increase in accounts receivables and inventory. The adjacent table presents a reconciliation of reported deal basis NWC to diligence NWC at Historical Balance Sheet dates and twelve - month average
Slide 73: MNK SGx adjusted NWC trend
Jun24 Jul24 Sep24 Oct24 Nov24 Dec24 Jan25 Feb25 Mar25 Apr24 May24 Accounts Receivable Aug24 Inventory 1 DSO: Trade AR / T3M gross sales x T3M days 2 DIO: Inventory less capitalized variances / T3M standard cost of sales x T3M days 3 DPO: AP / T3M (cost of sales + operating expense – Personnel) x T3M
Slide 74: Working capital — Endo GxSI
Working capital — Endo GxSI © Mallinckrodt Pharmaceuticals
Slide 75: Endo GxSI reported to definitional working capital
TTMMar 25 Avg Mar25 Dec24 Sep24 Jun24 Currency: $ m Ref Reported working capital: 0.2 0.2 0.2 0.2 0.2 Restricted cash and cash equivalents 196.3 202.1 213.1 197.1 173.1 Accounts receivable, net 249.4 183.4 196.2 251.2 366.7 Inventories, net 29.7 24.9 26.0 40.1 27.9 Prepaid expenses and OCA 475.6 410
Slide 76: Endo GxSI components of definitional working capital
(100.0) (200.0) (300.0) - 500.0 400.0 300.0 200.0 100.0 1 DSO: AR / T3M net revenue x T3M days 2 DIO: Inventory / T3M COGS (excl. royalty expense) x T3M days 3 DPO: AP / T3M (COGS + OPEX - Personnel - Lease expense) x T3M days Components of definitional working capital Dec24 Mar25 Inventory Other cu
Slide 77: Appendix
Appendix © Mallinckrodt Pharmaceuticals
Slide 78: Appendix A: MNK SGx reconciliation to segment reporting
A B C D E E Immaterial Differences As per 10k SpecGX SEC segment Less: MITH00 Less: Corpspinco Add: GXPN Mapping differences* Less: Intercompany Reported PL Currency: $ m 0.2 896.3 896.1 (0.1) - - - (61.1) 957.3 Net sales 0.2 607.9 607.7 - - - - (61.4) 669.1 Cost of sales 0.0 288.4 288.4 (0.1) - - -
Slide 79: Appendix B: MNK SGx reconciliation to carve-out financials FY23
402.5 (0.1) 402.6 (114.6) (0.8) (55.7) (0.7) (15.3) (0.0) 44.8 544.8 Net income / (loss) A B C D E F G H I Currency: $ m Add: Employee Add: Corporate Add: Perimeter Reported PL Less: I/C related allocations Add: Reorganization Add: Other adjustments Add: Tax Carve - out adjusted Difference Per COFS
Slide 80: Appendix B: MNK SGx reconciliation to carve-out financials FY24
Add: Employee Add: Corporate Add: Perimeter Currency: $ m Reported Less: I/C PL related allocations 122.5 0.2 122.3 (28.9) 4.3 (0.6) (1.3) (24.6) 1.1 40.4 131.8 Net income / (loss) A B C D E F G H I Add: Reorganization Add: Other adjustments Add: Tax Carve - out adjusted Difference Per COFS 901.3 0.
Slide 81: Appendix D: Endo GxSI reconciliation to Auditor's report
Appendix D: Endo GxSI reconciliation to Auditor’s report 2,011.5 72.5 859.1 1,079.9 (0.0) - - 1,079.9 Net revenues n/a n/a n/a n/a n/a 0.0 30.0 532.7 Cost of revenues n/a n/a n/a n/a n/a 0.1 4.2 58.5 SG&A n/a n/a n/a n/a n/a (0.0) 3.2 56.1 R&D 1,140.4 55.8 399.8 684.9 (0.0) 0.1 37.4 647.4 Costs and
Slide 82: Appendix E: Endo GxSI reconciliation to carve-out income statement FY23
Appendix E: Endo GxSI reconciliation to carve - out income statement – FY23 The table above represents the FY23 walk from the deal basis recast PL to the carve - out PL including (i) adjustments to include costs not directly attributed to the Endo GxSI cost centers but within the legal entity, (ii)
Slide 83: Appendix F: Endo GxSI reconciliation to carve-out income statement FY24
Appendix F: Endo GxSI reconciliation to carve - out income statement – FY24 The table above represents the FY 24 walk from the deal basis recast PL to the carve - out PL including (i) fresh start accounting related adjustments that was recorded in other segments but related to Endo GxSI, (ii) SAB 99
Slide 84: Appendix G: MNK SGx reconciliation from reported NWC to COFS
Appendix G: MNK SGx reconciliation from reported NWC to COFS Reconciliation to the COFS – Dec23 A B Reconciliation to the COFS – Dec24 A The reconciliations at left show the reconciliation between the as reported NWC and the COFS . Bridging items are as follows : A : JDE represents the as reported N
Slide 85: Appendix H: MNK SGx reconciliation to internal management reporting
Appendix H: MNK SGx reconciliation to internal Management reporting packages SAC and synergy Endo GxSI Combined MNK SGx Reconciliation to the internal management reporting packages – FY23 Management adjusted EBITDA FX Impacts Loss on Sale of Differences Assets Depreciation Rabbi Trust Performance Ma
Slide 86: Appendix I: Abbreviations
Appendix I: Abbreviations Names : Mallinckrodt Plc Client MNK SGx and Endo GxSI Combined Business or Par Health or Par MNK SGx’s management team Management (MNK SGx) Endo GxSI’s management team Management (Endo GxSI) Periods : Fiscal year ended December 30, 2023, 2024 FY23, FY24 Trailing twelve mont
Slide 87: Abbreviations (continued)
Abbreviations (continued) : Abbreviations (continued) : Overhead OH Goods and services tax GST Para - aminophenol PAP Gross to net GTN Prescription Drug User Fee Act PDUFA Head Count HC Proft and Loss PL Hyperion Financial Management (Oracle ERP) HFM Purchase price variance PPV Human Resources HR Pr